Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.63 |
| ▸ | KCNK9 | Q9NPC2 | 6/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690508 | 0.85 | MEN1 (0.68) | KCNK3KCNK9NR1H4KMT2ARAB9A | |
| SCHEMBL12314962 | 0.83 | KCNK9 (0.69) | KCNK3KCNK9NR1H4KMT2ASIRT1 | |
| SCHEMBL13152874 | 0.83 | NPC1 (0.60) | NR1H4KMT2ASIRT1RAB9AMEN1 | |
| SCHEMBL1690814 | 0.81 | ALDH1A1 (0.57) | KMT2ARAB9AMEN1POLBNLRP3 | |
| SCHEMBL22542978 | 0.81 | KCNK3 (0.71) | KCNK3KCNK9NR1H4KMT2ASIRT1 | |
| SCHEMBL8902663 | 0.81 | KCNK3 (0.71) | KCNK3KCNK9NR1H4KMT2ASIRT1 | |
| SCHEMBL20473774 | 0.81 | KCNK3 (0.71) | KCNK3KCNK9NR1H4KMT2ASIRT1 | |
| SCHEMBL13153532 | 0.81 | GRM4 (0.60) | KCNK3KCNK9SIRT1RAB9ANPC1 | |
| SCHEMBL27326763 | 0.81 | KCNK9 (0.65) | KCNK3KCNK9NR1H4KMT2ASIRT1 | |
| SCHEMBL6681834 | 0.80 | KCNK3 (0.69) | KCNK3KCNK9KMT2ASIRT1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | KCNK3 957/4885KCNK9 924/4885NR1H4 211/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | KCNK3 2100/4885KCNK9 3258/4885NR1H4 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.